## $Enkpkecn"Uk\,i\,pkhkecpeg"qh"\,O\,TK"kp"Rtquvcvg"Ecpegt"Fkc\,i\,pquku$

## Robert Jacob\*

Department of Medicine, University of Primorska, Koper, Slovenia

Corresponding author: Robert Jacob, Department of Medicine, University of Primorska, Koper, Slovenia, Email: Jacobrobert@hotmail.com

**Received:** 07-Oct-2022; Manuscript No. AOT-22-83260; **Editor assigned:** 12-Oct-2022, PreQc No. AOT-22-83260(PQ); **Reviewed:** 02-Nov-2022, QC No. AOT-22-83260; **Revised:** 11-Nov-2022, Manuscript No. AOT-22-83260(R); **Published:** 18-Nov-2022, DOI: 10.4172/aot.1000196.

Citation: Jacobs RV (2022)00Ninica%SignRiBance of MeN on Prostate Cancer Diagnosis. J M

However, this will primarily be accomplished by better identifying patients who are at an extremely low risk of csPCa and who can safely forgo biopsy. Should patients who have extremely suspect imaging findings forgo biopsy as well? Given the generally safe profile of

prostate biopsy, we think there is more to lose than gain in this situation. It is perhaps also important to keep in mind that medicine is about treating individuals, not their scans, in a time when images permeate every aspect of our lives.